Reversal of cardiomyopathy by suppression of frequent premature ventricular complexes - a prospective randomized clinical trial - Reversal of PVC-induced cardiomyopathy

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 70 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- CMP (LVEF < 50%) without identifiable cause (idiopathic) or post-infarction, > 6 months.
•- Optimal conventional heart failure therapy > 3 months.
•- Frequent monomorphic PVCs on Holter monitoring.
•* Frequent <= more than 15% of all QRS complexes are PVCs.
•* Monomorphic <= more than 75% of PVCs have the same morphology.
•- Greater than 18 years of age.
•- Willing and capable of giving informed consent.

•- Other causes of LV systolic dysfunction:
•* Significant valvular disease
•* Untreated hypertension (blood pressure > 140 mmHg)
•* Primary CMP (HCM, ARVC, LVNC, myocarditis, stress, peripartum)
•* Secondary CMP (infiltrative, storage, toxic, neuromuscular/neurological, autoimmune)
•- Electrocardiographic PVC characteristics suggestive of a focal origin not accessible by percutaneous approach.
•- Sustained supra-ventricular arrhythmia.
•- Evidence of significant CAD (>70% stenosis of a coronary artery) on coronary angiogram (CAG) or coronary CT necessitating revascularization (PCI / CABG) in the foreseeable future.
•- Signs of current myocardial ischemia on ECG (dynamic STT segments) or during exercise testing (significant ST segment depression/elevation).
•- Myocardial infarction within the last 6 calender months prior to enrollment.
•- PCI / CABG within the last 6 calender months prior to enrollment.
•- Physical status not allowing electrophysiological study (e.g. pregnancy or severe peripheral artery disease)
•- Presence of any disease, other than the patients cardiac disease, associated with a reduced likelihood of survival for the duration of the trial.

发起方

Medisch Universitair Ziekenhuis Maastricht